BL-8040 plus the anti PD-1, pembrolizumab, in the COMBAT trial demonstrates that effector T cells potentiate the benefit of chemotherapy in pancreatic ductal adenocarcinoma (PDAC) patients (117). Here, PDCD1 is linked to pancreatic ductal adenocarcinoma.